Biopharma buyers continue to shift deal-making spending away from M&A 10-Jan-2022 By Jane Byrne Strategic partnerships rather than M&A will be key for biopharma companies in 2022, finds a report from EY.
Pharma CEO confidence tops pre-pandemic levels, companies look to nucleic-acid technology assets to fuel growth 30-Sep-2021 By Jane Byrne CEOs at large pharma and biotech companies are upbeat when it comes to their outlook for both their own company and the industry at large; they also have a healthy appetite for M&A, found a KPMG survey.
AbCellera buys OrthoMab platform to move into bispecifics 24-Aug-2020 By Nick Taylor AbCellera buys OrthoMab platform from Dualogics to enable development of bispecific antibodies.
The journey to an approved Ebola vaccine 15-Nov-2019 By Ben Hargreaves Europe approved the first vaccine for the Ebola virus, but the path to reach this point has taken many years and required a global effort.
